This review paper below tells the role of ferroptosis in atherosclerosis. There are many papers supporting the role of ferroptosis in atherosclerosis, but there are also other opinions. So the discussion will continue and looks like one day ATH434 will be tested in this sense if ATH434 can slow down atherosclerosis.
The paper by Daniel Kosman et al, 2021 (The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells) comes very close to these mechanisms and gives me (perhaps only me) some support that ATH434 could prevent atherosclerosis and just by preventing ferroptosis of the endothelial cells.
This review is free and here is the abstract:The Chains of Ferroptosis Interact in the Whole Progression of Atherosclerosis
Xueqi Wan # 1, Huan Zhang # 1, Jinfan Tian # 1, Peng Hao 1, Libo Liu 1, Yuquan Zhou 1, Jing Zhang 1, Xiantao Song 1, Changjiang Ge 1AffiliationsPMCID: PMC10588755 DOI: 10.2147/JIR.S430885
- PMID: 37868832
Abstract
Atherosclerosis (AS), a category of cardiovascular disease (CVD) that can cause other more severe disabilities, increasingly jeopardizes human health. Owing to its imperceptible and chronic symptoms, it is hard to determine the pathogenesis and precise therapeutics for AS. A novel type of programmed cell death called ferroptosis was discovered in recent years that is distinctively different from other traditional cell death pathways in morphological and biochemical aspects. Characterized by iron overload, redox disequilibrium, and accumulation of lipid hydroperoxides (L-OOH), ferroptosis influences endothelial cells, vascular smooth muscle cells (VSMCs), and macrophages, as well as inflammation, partaking in the pathology of many cardiovascular diseases such as atherosclerosis, stroke, ischemia-reperfusion injury, and heart failure. The mechanisms behind ferroptosis are so sophisticated and interwoven that many molecules involved in this procedure are unknown. This review systematically depicts the initiation and modulation of ferroptosis and summarizes the contribution of ferroptosis to AS, which may open a feasible approach for target treatment in the alleviation of AS progression.
- Forums
- ASX - By Stock
- Ferroptosis in atherosclerosis
ATH
alterity therapeutics limited
Add to My Watchlist
0.00%
!
1.1¢

This review paper below tells the role of ferroptosis in...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $119.6M |
Open | High | Low | Value | Volume |
1.1¢ | 1.1¢ | 1.0¢ | $46.86K | 4.283M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
64 | 25268416 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 18128695 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
63 | 25148416 | 0.010 |
22 | 11669721 | 0.009 |
17 | 6584122 | 0.008 |
4 | 1380001 | 0.007 |
8 | 3400001 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 18128695 | 9 |
0.012 | 3480098 | 13 |
0.013 | 4872337 | 18 |
0.014 | 18433645 | 12 |
0.015 | 22174547 | 15 |
Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |